Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 97-112 , March 2006

Plasma and plasma products in the treatment of massive haemorrhage

  • Wendy N. Erber, MD, DPhil, FRCPA

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 1223 216 616; fax: +44 1223 216 407.
    • ,
  • David J. Perry, MD, PhD, FRCP, FRCPath, Cert Med Ed

References 

  1. Rutledge R, Sheldon GF, Collins ML. Massive transfusion. Crit Care Clin. 1986;2(4):791–805
  2. Patterson A. Massive transfusion. Int Anesthesiol Clin. 1987;25(1):61–74
  3. Hocker P, Hartmann T. Management of massive transfusion. Acta Anaesthesiol Scand Suppl. 1997;111:205–207
  4. Committee-on-Training . Advanced Trauma Life Support Program for Physicians. Chicago: American College of Surgeons; 1999;
  5. Garrioch MA. The body's response to blood loss. Vox Sang. 2004;87(supplement 1):74–76
  6. Hellstern P, Haubelt H. Indications for plasma in massive transfusion. Thromb Res. 2002;107(supplement 1):S19–S22
  7. Erber WN. Massive blood transfusion in the elective surgical setting. Transfus Apher Sci. 2002;27(1):83–92
  8. Hewson JR, Neame PB, Kumar N, et al. Coagulopathy related to dilution and hypotension during massive transfusion. Crit Care Med. 1985;13(5):387–391
  9. Murray DJ, Olson J, Strauss R, Tinker JH. Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology. 1988;69(6):839–845
  10. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995;81(2):360–365
  11. Rohrer MJ, Natale AM. Effect of hypothermia on the coagulation cascade. Crit Care Med. 1992;20(10):1402–1405
  12. Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth. 2000;85(3):487–491
  13. Leslie SD, Toy PT. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid. Am J Clin Pathol. 1991;96(6):770–773
  14. Counts RB, Haisch C, Simon TL, Maxwell NG, Heimbach DM, Carrico CJ. Hemostasis in massively transfused trauma patients. Ann Surg. 1979;190(1):91–99
  15. Lawson JH, Murphy MP. Challenges for providing effective hemostasis in surgery and trauma. Semin Hematol. 2004;41(1 Suppl 1):55–64
  16. Reed RL, Ciavarella D, Heimbach DM, Baron L, Pavlin E, Counts RB, et al. Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. Ann Surg. 1986;203(1):40–48
  17. Blauhut, B., Lundsgaard, H. Blutverlust und Verbrennungen in der operativen Medizin. In Transfusionmedizin. C. Mueller-Eckhardt (Hrsg). Auflage-Verlag. 1996. 291–320.
  18. Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement. A study of 172 cases. Vox Sang. 1982;42(3):113–123
  19. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247–2256
  20. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11–28
  21. Ciavarella D, Reed RL, Counts RB, Baron L, Pavlin E, Heimbach DM, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol. 1987;67(3):365–368
  22. Hellstern P, Halbmayer WM, Kohler M, Seitz R, Muller-Berghaus G. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999;95(4 supplement 1):S3–S6
  23. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115(4):998–1001
  24. Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G, et al. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost. 1995;73(4):675–679
  25. Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EG, Lowe GD, et al. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost. 1996;76(1):23–28
  26. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116(3):619–624
  27. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis. 1990;1(3):307–317
  28. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55(6):638–648
  29. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost. 2000;26(4):385–391
  30. Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004;10(4):352–359
  31. Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003;55(5):886–891
  32. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol. 2004;141(1 supplement 1):140–144
  33. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res. 1989;56(5):603–609
  34. Radosevich M, Goubran HI, Burnouf T. Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang. 1997;72(3):133–143
  35. Carless PA, Anthony DM, Henry DA. Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg. 2002;89(6):695–703
  36. Jackson MR, MacPhee MJ, Drohan WN, Alving BM. Fibrin sealant: current and potential clinical applications. Blood Coagul Fibrinolysis. 1996;7(8):737–746
  37. Hoyt DB. A clinical review of bleeding dilemmas in trauma. Semin Hematol. 2004;41(1 supplement 1):40–43
  38. Hulka F, Mullins RJ, Frank EH. Blunt brain injury activates the coagulation process. Arch Surg. 1996;131(9):923–927discussion 927–928
  39. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354(9193):1879
  40. Kenet G. The Use of Recombinant Factor VIIa for Hemorrhage Control in Trauma Patients. Transfusion Alternatives in Transfusion Medicine. 2003;5(5):48–50
  41. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57(4):709–719
  42. Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol. 1999;104(2):208–219
  43. Linden MD. The hemostatic defect of cardiopulmonary bypass. J Thromb Thrombolysis. 2003;16(3):129–147
  44. Hunt BJ, Parratt RN, Segal HC, Sheikh S, Kallis P, Yacoub M. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg. 1998;65(3):712–718
  45. Smith CR. Management of bleeding complications in redo cardiac operations. Ann Thorac Surg. 1998;65(4 Suppl):S2–S8discussion S27–28
  46. MacGillivray TE. Fibrin sealants and glues. J Card Surg. 2003;18(6):480–485
  47. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb. 2002;32(supplement 1):41–46
  48. Aggarwal A, Catlett J, Alcorn K. Use of recombinant activated factor VII (rVIIa) in the management of intractable bleeding in surgical and trauma patients. ASH 43rd Annual Meeting. 2001: Abstract 3883.
  49. Karkouti K, Scott Beattie W, Wijeysundera WN, Yau TM, McCluskey SA, Ghannam M, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26–34
  50. Silva MA, Muralidharan V, Mirza DF. The management of coagulopathy and blood loss in liver surgery. Semin Hematol. 2004;41(1 supplement 1):132–139
  51. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71(3):402–405
  52. Escobar M, Hoots W. Transfusion alternatives in transfusion medicine. TATM Journal. 2003;5:37–39
  53. Lodge JP. Hemostasis in liver resection surgery. Semin Hematol. 2004;41(1 supplement 1):70–75
  54. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion. 2003;43(12):1711–1716
  55. Cohen JR, Angus L, Asher A, Chang JB, Wise L. Disseminated intravascular coagulation as a result of supraceliac clamping: implications for thoracoabdominal aneurysm repair. Ann Vasc Surg. 1987;1(5):552–557
  56. Anagnostopoulos PV, Shepard AD, Pipinos II, Raman SB, Chaudhry PA, Mishima T, et al. Hemostatic alterations associated with supraceliac aortic cross-clamping. J Vasc Surg. 2002;35(1):100–108
  57. Vahl AC, Mackaay AJ, Huijgens PC, Scheffer GJ, Rauwerda JA. Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping. Eur J Vasc Endovasc Surg. 1997;13(1):60–65
  58. Illig KA, Green RM, Ouriel K, Riggs PN, Bartos S, Whorf R, et al. Primary fibrinolysis during supraceliac aortic clamping. J Vasc Surg. 1997;25(2)(244-51):252–254
  59. Haithcock BE, Shepard AD, Raman SB, Conrad MF, Pandurangi K, Fanous NH. Activation of fibrinolytic pathways is associated with duration of supraceliac aortic cross-clamping. J Vasc Surg. 2004;40(2):325–333
  60. Adam DJ, Haggart PC, Ludlam CA, Bradbury AW. von Willebrand factor and platelet count in ruptured abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg. 2003;26(4):412–417
  61. Bonnar J. Massive obstetric haemorrhage. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(1):1–18
  62. Bouwmeester FW, Jonkhoff AR, Verheijen RH, van Geijn HP. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol. 2003;101(6):1174–1176
  63. Segal S, Shemesh IY, Blumenthal R, Yoffe B, Laufer N, Ezra Y, et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet. 2003;268(4):266–267
  64. Boehlen F, Morales MA, Fontana P, Ricou B, Irion O, de Moerloose P. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. Bjog. 2004;111(3):284–287
  65. Niemi T, Svartling N, Syrjala M, Asko-Seljavaara S, Rosenberg P. Haemostatic disturbances in burned patients during early excision and skin grafting. Blood Coagul Fibrinolysis. 1998;9(1):19–28
  66. Garcia-Avello A, Lorente JA, Cesar-Perez J, Garcia-Frade LJ, Alvarado R, Arevalo JM, et al. Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. Thromb Res. 1998;89(2):59–64
  67. Bianchi A, Jackson D, Maitz P, Thanakrishnan G. Treatment of bleeding with recombinant factor VIIa in a patient with extensive burns. Thromb Haemost. 2004;91(1):203–204

PII: S1521-6926(05)00027-7

doi: 10.1016/j.beha.2005.01.026

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 97-112 , March 2006

Article Tools